2024
The role of international renal disaster preparedness working groups in difficult settings: bridge over troubled water
Yoo K, Chao C, Lee J, Abu-Alfa A. The role of international renal disaster preparedness working groups in difficult settings: bridge over troubled water. Current Opinion In Nephrology & Hypertension 2024, 33: 636-640. PMID: 39234876, DOI: 10.1097/mnh.0000000000001024.Peer-Reviewed Original ResearchCapacity for the management of kidney failure in the International Society of Nephrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA)
Karam S, Amouzegar A, Alshamsi I, Al Ghamdi S, Anwar S, Ghnaimat M, Saeed B, Arruebo S, Bello A, Caskey F, Damster S, Donner J, Jha V, Johnson D, Levin A, Malik C, Nangaku M, Okpechi I, Tonelli M, Ye F, Abu-Alfa A, Savaj S, Authors R, Abou-Jaoudeh P, Al Hussain T, Al Salmi I, Alrukhaimi M, Alyousef A, Bahous S, Cai G, Hassan H, Cho Y, Davids M, Davison S, Diongole H, Divyaveer S, Ekrikpo U, Ethier I, Fung W, Ghimire A, Hooman N, Houston G, Htay H, Ibrahim K, Irish G, Jindal K, Kelly D, Lalji R, Mitwali A, Mortazavi M, Nalado A, Neuen B, Olanrewaju T, Osman M, Ossareh S, Petrova A, Riaz P, Saad S, Sakajiki A, See E, Sozio S, Tiv S, Tungsanga S, Viecelli A, Wainstein M, Wannous H, Yeung E, Zaidi D. Capacity for the management of kidney failure in the International Society of Nephrology Middle East region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA). Kidney International Supplements 2024, 13: 57-70. PMID: 38618498, PMCID: PMC11010631, DOI: 10.1016/j.kisu.2024.01.009.Peer-Reviewed Original ResearchChronic kidney disease registryImprovement of early detectionHealth-related quality-of-life scoresLower health-related quality-of-life scoresGlobal Kidney Health AtlasChronic kidney diseaseHealth information systemsConservative kidney managementLevels of careBurden of kidney diseaseQuality-of-life scoresPrevalence of chronic kidney diseaseManagement of kidney failureIncidence of kidney transplantationKidney failure treated with dialysisSymptom burdenKidney diseaseKidney managementPeritoneal dialysisTailored guidelinesKidney transplantationKidney failureMiddle East regionEast regionRegistryImpact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
Elkeraie A, Al-Ghamdi S, Abu-Alfa A, Alotaibi T, AlSaedi A, AlSuwaida A, Arici M, Ecder T, Ghnaimat M, Hafez M, Hassan M, Sqalli T. Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective. International Journal Of Nephrology And Renovascular Disease 2024, 17: 1-16. PMID: 38196830, PMCID: PMC10771977, DOI: 10.2147/ijnrd.s430532.Peer-Reviewed Original ResearchChronic kidney diseaseSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsDiabetes mellitusKidney diseaseType 2 diabetes mellitusMajor public health concernAldosterone system inhibitorsBetter clinical outcomesCause of deathPublic health concernNephrology referralCKD managementClinical outcomesSystem inhibitorsCardioprotective propertiesEarly initiationTreatment pathwaysConsensus recommendationsHigh riskPatientsBetter careHealth concernEarly detectionHypertension
2023
Chronic Kidney Disease Management in the Middle East and Africa: Concerns, Challenges, and Novel Approaches
Al-Ghamdi S, Abu-Alfa A, Alotaibi T, AlSaaidi A, AlSuwaida A, Arici M, Ecder T, Koraie A, Ghnaimat M, Hafez M, Hassan M, Sqalli T. Chronic Kidney Disease Management in the Middle East and Africa: Concerns, Challenges, and Novel Approaches. International Journal Of Nephrology And Renovascular Disease 2023, 16: 103-112. PMID: 37051319, PMCID: PMC10084934, DOI: 10.2147/ijnrd.s363133.Peer-Reviewed Original ResearchChronic kidney diseaseManagement of CKDChronic kidney disease managementKidney disease managementManagement of patientsNovel therapeutic optionsTherapeutic optionsKidney diseaseProtective therapyOverall burdenEarly diagnosisAvailable evidenceDisease managementHealthcare specialistsHealthcare systemHealthcare policyPatientsSteering CommitteeBurdenRiskHypertensionComorbiditiesDiabetesReferralTherapy
2021
International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East
Amouzegar A, Abu-Alfa AK, Alrukhaimi MN, Bello AK, Ghnaimat MA, Johnson DW, Jha V, Harris DCH, Levin A, Tonelli M, Lunney M, Saad S, Khan M, Zaidi D, Osman MA, Ye F, Okpechi IG, Ossareh S, Board I. International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East. Kidney International Supplements 2021, 11: e47-e56. PMID: 33981470, PMCID: PMC8084726, DOI: 10.1016/j.kisu.2021.01.002.Peer-Reviewed Original ResearchChronic kidney diseaseKidney replacement therapyKidney diseaseKidney failureKidney careReplacement therapyNephrology Global Kidney Health AtlasNondialysis chronic kidney diseaseGlobal Kidney Health AtlasPeritoneal dialysis servicesHealth care fundingKidney transplantationDialysis RegistryKidney functionTransplantation servicesHigh burdenPermanent impairmentDialysis servicesDisease strategiesHemodialysis servicesHealth information systemsHealth AtlasSustainable health information systemsDiseaseCare fundingControversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
Babitt J, Eisenga M, Haase V, Kshirsagar A, Levin A, Locatelli F, Małyszko J, Swinkels D, Tarng D, Cheung M, Jadoul M, Winkelmayer W, Drüeke T, Participants C, Abu-Alfa A, Afsar B, Pai A, Besarab A, Moore G, Casadevall N, Cases A, de Francisco A, Eckardt K, Fishbane S, Fried L, Ganz T, Ginzburg Y, Gómez R, Goodnough L, Hamano T, Hanudel M, Hao C, Iseki K, Ix J, Johansen K, Ketteler M, Kovesdy C, Leaf D, Macdougall I, Massy Z, McMahon L, Minutolo R, Nakanishi T, Nemeth E, Obrador G, Parfrey P, Park H, Pecoits-Filho R, Robinson B, Roger S, Shah Y, Spinowitz B, Tanaka T, Tsukamoto Y, Tungsanga K, Walther C, Wang A, Wolf M. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International 2021, 99: 1280-1295. PMID: 33839163, DOI: 10.1016/j.kint.2021.03.020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseAnemia guidelinesHypoxia-inducible factor prolyl hydroxylase inhibitorOptimal anemia managementErythropoiesis-stimulating agentsTreatment of anemiaIron homeostasisSignificant adverse consequencesControversies ConferenceIron therapyAnemia managementRandomized trialsDiagnostic challengePatient outcomesEpidemiological studiesHydroxylase inhibitorTreatment targetsGlobal outcomeLatest evidenceDiseaseAnemiaPrevious recommendationsAdverse consequencesOngoing controversy
2020
Collagenofibrotic glomerulopathy in a kidney transplant recipient: A first report
Jdiaa SS, Moeckel GW, Kfoury H, Medawar WA, Abu‐Alfa A. Collagenofibrotic glomerulopathy in a kidney transplant recipient: A first report. American Journal Of Transplantation 2020, 21: 1948-1952. PMID: 33206467, DOI: 10.1111/ajt.16399.Peer-Reviewed Case Reports and Technical NotesConceptsKidney transplant recipientsCollagenofibrotic glomerulopathyTransplant recipientsRenal dysfunctionType 3 fibresProgressive diseaseKidney diseaseDefinitive diagnosisUnknown causeRare diseaseDiseaseFirst caseRecipientsFirst reportHematuriaProteinuriaGlomerulopathyPatientsDysfunctionGlomeruliDiagnosisProgressionKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation
Małyszko J, Bamias A, Danesh F, Dębska-Ślizień A, Gallieni M, Gertz M, Kielstein J, Tesarova P, Wong G, Cheung M, Wheeler D, Winkelmayer W, Porta C, Participants C, Abu-Alfa A, Amer H, Beutel G, Chapman J, Chen X, Chudek J, Cosmai L, Danesi R, De Stefano F, Iseki K, Jaimes E, Jhaveri K, Jurczyszyn A, Kazancioğlu R, Kitchlu A, Kollmannsberger C, Lahoti A, Li Y, Macía M, Matsubara T, Mitropoulos D, Noiri E, Perazella M, Ronco P, Rosner M, Romeo M, Sprangers B, Stadler W, Stevens P, Tesař V, da Costa e Silva V, Vesole D, Vijayan A, Viklický O, Workeneh B, Yanagita M, Zakharova E. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International 2020, 98: 1407-1418. PMID: 33276867, DOI: 10.1016/j.kint.2020.07.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseHematological malignanciesControversies ConferenceKidney transplantationModerate stage chronic kidney diseaseKDIGO Controversies ConferenceAcute kidney injuryKidney transplant recipientsBurden of cancerKidney injuryTransplant recipientsKidney transplantRegistry analysisMultiple myelomaClinical challengeCancer riskGlobal outcomeMalignancyCancerPatientsDiseaseTransplantationBidirectional relationshipRiskKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer
Porta C, Bamias A, Danesh F, Dębska-Ślizień A, Gallieni M, Gertz M, Kielstein J, Tesarova P, Wong G, Cheung M, Wheeler D, Winkelmayer W, Małyszko J, Participants C, Abu-Alfa A, Amer H, Beutel G, Chapman J, Chen X, Chudek J, Cosmai L, Danesi R, De Stefano F, Iseki K, Jaimes E, Jhaveri K, Jurczyszyn A, Kazancioğlu R, Kitchlu A, Kollmannsberger C, Lahoti A, Li Y, Macía M, Matsubara T, Mitropoulos D, Noiri E, Perazella M, Ronco P, Rosner M, Romeo M, Sprangers B, Stadler W, Stevens P, Tesař L, da Costa e Silva V, Vesole D, Vijayan A, Viklický O, Workeneh B, Yanagita M, Zakharova E. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney International 2020, 98: 1108-1119. PMID: 33126977, DOI: 10.1016/j.kint.2020.06.046.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseSolid organ malignanciesControversies ConferenceKidney impairmentKidney diseaseKidney cancerKDIGO Controversies ConferenceSetting of malignancyIncidence of cancerAreas of controversyOrgan malignanciesTreatment landscapeKidney functionOncology patientsMedical oncologyPalliative careRenal issuesPatient outcomesNovel therapiesCritical careMalignancyAnticancer treatmentCancerPatientsCancer treatmentFramework for establishing integrated kidney care programs in low- and middle-income countries
Tonelli M, Nkunu V, Varghese C, Abu-Alfa AK, Alrukhaimi MN, Bernieh B, Fox L, Gill J, Harris D, Hou F, O’Connell P, Rashid H, Niang A, Ossareh S, Tesar V, Zakharova E, Yang C. Framework for establishing integrated kidney care programs in low- and middle-income countries. Kidney International Supplements 2020, 10: e19-e23. PMID: 32149006, PMCID: PMC7031683, DOI: 10.1016/j.kisu.2019.11.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic kidney diseaseKidney care programKidney replacement therapyKidney failureKidney diseaseKidney careMiddle-income countriesReplacement therapyCare programAcute kidney injuryUrgent public health needPublic health needsKidney injuryKidney transplantationPrimary preventionPreventive careRisk factorsNoncommunicable diseasesTimely managementKidney disordersHealth needsMild formHealth systemDiseaseTherapyConsiderations on equity in management of end-stage kidney disease in low- and middle-income countries
Van Biesen W, Jha V, Abu-Alfa AK, Andreoli SP, Ashuntantang G, Bernieh B, Brown E, Chen Y, Coppo R, Couchoud C, Cullis B, Douthat W, Eke FU, Hemmelgarn B, Hou FF, Levin NW, Luyckx VA, Morton RL, Moosa MR, Murtagh FEM, Richards M, Rondeau E, Schneditz D, Shah KD, Tesar V, Yeates K, Garcia G. Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. Kidney International Supplements 2020, 10: e63-e71. PMID: 32149010, PMCID: PMC7031686, DOI: 10.1016/j.kisu.2019.11.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEnd-stage kidney diseaseMiddle-income countriesKidney diseaseHealth systemFull health potentialOverall health care spendingHealth care spendingTherapy programHealth potentialCare spendingDiseaseDelivery modelEquitable provisionEquitable implementationKRTPrevalenceIncidenceIssues of availabilitySuggest areas
2019
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
House A, Wanner C, Sarnak M, Piña I, McIntyre C, Komenda P, Kasiske B, Deswal A, deFilippi C, Cleland J, Anker S, Herzog C, Cheung M, Wheeler D, Winkelmayer W, McCullough P, Participants C, Abu-Alfa A, Amann K, Aonuma K, Appel L, Baigent C, Bakris G, Banerjee D, Boletis J, Bozkurt B, Butler J, Chan C, Costanzo M, Dubin R, Filippatos G, Gikonyo B, Gikonyo D, Hajjar R, Iseki K, Ishii H, Knoll G, Lenihan C, Lentine K, Lerma E, Macedo E, Mark P, Noiri E, Palazzuoli A, Pecoits-Filho R, Pitt B, Rigatto C, Rossignol P, Setoguchi S, Sood M, Störk S, Suri R, Szummer K, Tang S, Tangri N, Thompson A, Vijayaraghavan K, Walsh M, Wang A, Weir M. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2019, 95: 1304-1317. PMID: 31053387, DOI: 10.1016/j.kint.2019.02.022.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseDialysis-dependent chronic kidney diseaseNondialysis chronic kidney diseaseHeart failureKidney diseaseEjection fractionGlobal outcomeKidney transplant patientsReduced ejection fractionControversies ConferenceTransplant patientsBreakout group discussionsDiseaseOutcomesFailureHFpEFPatientsGroup discussionsPrevalenceIncidenceDiagnosisPreventionDialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Chan C, Blankestijn P, Dember L, Gallieni M, Harris D, Lok C, Mehrotra R, Stevens P, Wang A, Cheung M, Wheeler D, Winkelmayer W, Pollock C, Participants C, Abu-Alfa A, Bargman J, Bleyer A, Brown E, Davenport A, Davies S, Finkelstein F, Flythe J, Goffin E, Golper T, Gómez R, Hamano T, Hecking M, Heimbürger O, Hole B, Hothi D, Ikizler T, Isaka Y, Iseki K, Jha V, Kawanishi H, Kerr P, Komenda P, Kovesdy C, Lacson E, Laville M, Lee J, Lerma E, Levin N, Lichodziejewska-Niemierko M, Liew A, Lindley E, Lockridge R, Madero M, Massy Z, McCann L, Meyer K, Morton R, Nadeau-Fredette A, Okada H, Perez J, Perl J, Polkinghorne K, Riella M, Robinson B, Rocco M, Rosansky S, Rotmans J, Roblero M, Tangri N, Tonelli M, Tong A, Tsukamoto Y, Tungsanga K, Vachharajani T, van Loon I, Watnick S, Weiner D, Wilkie M, Zakharova E. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2019, 96: 37-47. PMID: 30987837, DOI: 10.1016/j.kint.2019.01.017.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEnd-stage kidney diseaseDialysis initiationKidney diseaseModality choiceGoals of careNumber of patientsPatient-centered goalsDiverse health care systemsHealth care jurisdictionsAreas of controversyHealth care systemControversies ConferenceMaintenance dialysisDialysis modalityPatient goalsPatient educationIndividualized carePatient involvementPatient experienceGlobal outcomeCare systemDialysisPatientsOutcomesDisease
2018
Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Eckardt K, Bansal N, Coresh J, Evans M, Grams M, Herzog C, James M, Heerspink H, Pollock C, Stevens P, Tamura M, Tonelli M, Wheeler D, Winkelmayer W, Cheung M, Hemmelgarn B, Participants C, Abu-Alfa A, Anand S, Arici M, Ballew S, Block G, Burgos-Calderon R, Charytan D, Das-Gupta Z, Dwyer J, Fliser D, Froissart M, Gill J, Griffith K, Harris D, Huffman K, Inker L, Jager K, Jun M, Kalantar-Zadeh K, Kasiske B, Kovesdy C, Krane V, Lamb E, Lerma E, Levey A, Levin A, Mauro J, Nash D, Navaneethan S, O’Donoghue D, Obrador G, Pecoits-Filho R, Robinson B, Schäffner E, Segev D, Stengel B, Stenvinkel P, Tangri N, Tentori F, Tsukamoto Y, Turakhia M, Vazquez M, Wang A, Williams A. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2018, 93: 1281-1292. PMID: 29656903, PMCID: PMC5998808, DOI: 10.1016/j.kint.2018.02.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGlomerular filtration rateKidney replacement therapyCKD G4Kidney failureFiltration rateRisk factorsGlobal outcomeTraditional CVD risk factorsCKD Prognosis ConsortiumCVD risk factorsCardiovascular disease eventsPrognosis of patientsOptimal therapeutic strategyControversies ConferenceCohort studyCVD outcomesHeart failureVariable prognosisClinical outcomesTherapeutic challengeKidney diseasePrognostic valueReplacement therapyInternational expert groupPatient preferencesKidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Swanepoel C, Atta M, D’Agati V, Estrella M, Fogo A, Naicker S, Post F, Wearne N, Winkler C, Cheung M, Wheeler D, Winkelmayer W, Wyatt C, Participants C, Abu-Alfa A, Adu D, Agodoa L, Alpers C, Arogundade F, Ashuntantang G, Bagnis C, Bhimma R, Brocheriou I, Cohen A, Cohen K, Cook H, de Seigneux S, Fabian J, Finkelstein F, Haas M, Hamzah L, Hendry B, Imonje V, Jennette J, Kimmel P, Klotman M, Klotman P, Larsen C, McCulloch M, Mosiane P, Nast C, Okpechi I, Ray P, Rosenberg A, Ross M, Ryom L, Truong L, Ulasi I, Vogt L, Zeier M. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2018, 93: 545-559. PMID: 29398134, PMCID: PMC5983378, DOI: 10.1016/j.kint.2017.11.007.Peer-Reviewed Original ResearchConceptsHIV-positive individualsKidney diseaseAntiretroviral therapyHIV infectionImmune complex kidney diseaseKidney disease preventionHIV-associated nephropathyFocal segmental glomerulosclerosisUnique HIVKidney injuryOpportunistic infectionsHIV treatmentClinical guidelinesRenal pathologySegmental glomerulosclerosisGeneral populationRole of geneticsGlobal outcomeDisease preventionNatural historyInfectious diseasesDiseaseInfectionGenetic factorsPrevention
2013
Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients
Abou-Mrad RM, Abu-Alfa AK, Ziyadeh FN. Effects of weight reduction regimens and bariatric surgery on chronic kidney disease in obese patients. American Journal Of Physiology. Renal Physiology 2013, 305: f613-f617. PMID: 23825072, DOI: 10.1152/ajprenal.00173.2013.BooksConceptsChronic kidney diseaseKidney diseaseBariatric surgeryModerate chronic kidney diseaseWeight reduction regimensIntentional weight lossRenal functional changesWeight loss interventionHigh-protein dietGlomerular hyperfiltrationPerioperative complicationsObese patientsRenal damageLoss interventionAdvanced stageFunctional changesModest riskWeight lossDiseaseAlbuminuriaObesityPatientsSurgeryBeneficial reductionHypertension
2011
Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
Abu-Alfa AK. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. Advances In Kidney Disease And Health 2011, 18: 188-198. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryNephrogenic systemic fibrosisGadolinium-based contrast agentsCKD stage 4Immediate hemodialysisSystemic fibrosisAdministration of GBCAsCare of patientsStage 4Needs of patientsMajority of casesKidney injuryDialysis initiationPeritoneal dialysisSignificant morbidityKidney diseaseCurrent recommendationsHigh riskContrast agentsLower riskRisk differencePatientsDrug AdministrationHemodialysisIndividualized assessment
2008
Nephrogenic systemic fibrosis—Implications for nephrologists
Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis—Implications for nephrologists. European Journal Of Radiology 2008, 66: 208-212. PMID: 18342470, DOI: 10.1016/j.ejrad.2008.01.028.BooksConceptsRisk of NSFChronic kidney diseaseNephrogenic systemic fibrosisContrast-induced nephropathyAdvanced chronic kidney diseaseDevelopment of NSFAdministration of gadoliniumErythropoietin therapyNephrologist's perspectiveKidney diseaseMetabolic acidosisRisk factorsMineral metabolismSystemic fibrosisNephrologist's roleHigh dosesGd-CARecent evidenceRiskContrast agentsNephropathyNephrologistsPatientsFibrosisAcidosisThe association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis*
Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlata D, Globe D, Audhya P. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis*. Current Medical Research And Opinion 2008, 24: 1091-1100. PMID: 18328118, DOI: 10.1185/030079908x280653.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseErythropoiesis-stimulating agentsHealth-related qualityDarbepoetin alfaWeek 52Week 12Kidney diseasePatients' health-related qualityGeneral CKD populationQ2W darbepoetin alfaWeek darbepoetin alfaGlomerular filtration rateSingle-arm studyBenefits of treatmentMean Hb concentrationYears of ageSubject inclusion criteriaCKD populationCreatinine clearanceHemoglobin levelsHb targetHb levelsHRQOL measuresFiltration rateInclusion criteriaThe Impact of NSF on the Care of Patients With Kidney Disease
Abu-Alfa A. The Impact of NSF on the Care of Patients With Kidney Disease. Journal Of The American College Of Radiology 2008, 5: 45-52. PMID: 18180009, DOI: 10.1016/j.jacr.2007.08.018.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic kidney diseaseNephrogenic systemic fibrosisGlomerular filtration rateCare of patientsGadolinium-based magnetic resonance contrast agentsRenal diseasePeritoneal dialysisKidney diseaseFiltration rateSystemic fibrosisStage 4 chronic kidney diseaseCases of NSFNormal glomerular filtration rateAcute kidney injurySessions of hemodialysisMajority of casesCKD patientsKidney injuryMagnetic resonance contrast agentsSignificant morbidityPD patientsVascular accessProlonged eliminationOdds ratio